KRAS and neoplasm: Peripheral blood lymphocytes transduced with these TCRs can also detect mutated KRAS neoantigens in HLA‐A * 11: 01+ tumor cell lines and reduce tumor growth in xenograft cancer models.[77] Identifying tumor‐specific neoantigen encoded by mutant genes is limited to resident and infiltrated CD8+ T cells in tumor tissue.